Pinealon research: studies, doses and safety

A peptide with unproven brain benefits and no established injection dose.

Also called: EDR, Glu-Asp-Arg, glutamyl-aspartyl-arginine.

Khavinson bioregulator peptides · Synthetic tripeptide studied for nerve-cell protection.

A small worker study used oral Pinealon twice daily for two weeks; this does not establish an injection course.

14 human reports or summaries may reuse some participants. Independent trials have not confirmed a benefit.

Key studies

  • Head injury: patent example: A patent describes human IM exposure, with major reporting gaps. (source)
  • Mixed brain disorders: internal report: An internal oral-use report suggests symptom changes but cannot establish benefit or safety. (source)
  • Head injury: review-described cohort: A review reports oral human exposure but lacks usable comparative outcome numbers. (source)
  • Older adults: emotional symptoms: This report is part of the human record, but its detailed dosing remains unverified. (source)
  • Locomotive workers: oral course: Work and health scores changed after oral dosing; causation is uncertain. (source)
  • Locomotive workers: companion report: The abstract confirms a 100 mcg twice-daily oral schedule. (source)

Related to Pinealon

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.